迈瑞医疗拟赴港交所主板上市

Core Viewpoint - Mindray Medical plans to issue H-shares and list on the Hong Kong Stock Exchange to support its internationalization strategy and business development [1] Group 1: H-share Issuance - The number of H-shares to be issued will not exceed 10% of the total share capital post-issuance, with an overallotment option of up to 15% [1] - The funds raised will be used for international strategy advancement, global business expansion, increased R&D investment, and operational funding [1] Group 2: Financial Performance - Mindray Medical's revenue for 2022, 2023, and 2024 was 30.366 billion, 34.932 billion, and 36.726 billion yuan, reflecting year-on-year growth of 20.17%, 15.04%, and 5.14% respectively [1] - The net profit attributable to shareholders for the same years was 9.007 billion, 11.582 billion, and 11.689 billion yuan, with year-on-year growth of 20.07%, 20.56%, and 0.75% respectively [1] Group 3: R&D Investment - R&D investment for 2022, 2023, and 2024 was 3.191 billion, 3.779 billion, and 4.008 billion yuan, representing 10.51%, 10.82%, and 10.91% of revenue respectively [2] - Mindray Medical has established a global R&D network with twelve major centers across Asia, North America, and Europe, and has filed 11,773 patent applications as of the end of 2024 [2] Group 4: Recent Performance Trends - In the first half of 2025, Mindray Medical reported revenue of 16.743 billion yuan, a year-on-year decline of 18.45%, and a net profit of 5.069 billion yuan, down 32.96% [2] - The company anticipates positive revenue growth in Q3 2025, with a trend of sequential improvement in revenue [2]